A Review of Phase 3 Trials of Dupilumab for the Treatment of Atopic Dermatitis in Adults, Adolescents, and Children Aged 6 and Up

被引:11
作者
Cather, Jennifer [1 ]
Young, Melodie [1 ]
DiRuggiero, Douglas C. [2 ]
Tofte, Susan [3 ]
Williams, Linda [4 ]
Gonzalez, Tayler [5 ]
机构
[1] Mindful Dermatol & Modern Res Associates, Dallas, TX USA
[2] Skin Canc & Cosmet Dermatol Ctr, Rome, GA USA
[3] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[4] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA
[5] Sanofi, Cambridge, MA 02139 USA
关键词
Atopic dermatitis; Dupilumab; Efficacy; Safety; Adults; Children; Adolescents; PERSISTENT ASTHMA; SYSTEMIC THERAPY; INCREASED RISK; MODERATE; PLACEBO; HUMANIZATION; INFECTIONS; MANAGEMENT; HEALTH; SAFETY;
D O I
10.1007/s13555-022-00778-y
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Atopic dermatitis (AD) is a chronic pruritic skin disease that can have a profound negative impact on patients' quality of life, especially in cases of inadequate disease control. Dupilumab, a dual inhibitor of IL-4 and IL-13 signaling, is approved in the United States for the treatment of moderate-to-severe AD in adults (>= 18 years old) and in children (>= 6 years old). In this review, we present results from phase 3 trials evaluating dupilumab's efficacy and safety in adults, adolescents, and children. These trials demonstrate that dupilumab provides rapid improvements (in as little as 1 week) and sustained efficacy (up to 4 years) when used as a treatment for moderate-to-severe AD. Dupilumab not only improves skin signs and symptoms, but also provides multiple health benefits beyond the skin, including improvements in quality of life, itch, sleep disturbances, and pain/discomfort. Dupilumab is generally well tolerated, has a favorable safety profile in adults, adolescents, and children, has no serious drug-drug interactions, does not require routine laboratory testing, and is not an immunosuppressant. Taken together, phase 3 trials demonstrate that dupilumab provides rapid and sustained efficacy and is generally well tolerated for the treatment of moderate-to-severe AD across age groups.
引用
收藏
页码:2013 / 2038
页数:26
相关论文
共 58 条
[1]   Conjunctivitis in dupilumab clinical trials [J].
Akinlade, B. ;
Guttman-Yassky, E. ;
de Bruin-Weller, M. ;
Simpson, E. L. ;
Blauvelt, A. ;
Cork, M. J. ;
Prens, E. ;
Asbell, P. ;
Akpek, E. ;
Corren, J. ;
Bachert, C. ;
Hirano, I. ;
Weyne, J. ;
Korotzer, A. ;
Chen, Z. ;
Hultsch, T. ;
Zhu, X. ;
Davis, J. D. ;
Mannent, L. ;
Hamilton, J. D. ;
Teper, A. ;
Staudinger, H. ;
Rizova, E. ;
Pirozzi, G. ;
Graham, N. M. H. ;
Shumel, B. ;
Ardeleanu, M. ;
Wollenberg, A. .
BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 (03) :459-473
[2]   Clinical use of anti-TNF therapy and increased risk of infections [J].
Ali, Tauseef ;
Kaitha, Sindhu ;
Mahmood, Sultan ;
Ftesi, Abdul ;
Stone, Jordan ;
Bronze, Michael S. .
DRUG HEALTHCARE AND PATIENT SAFETY, 2013, 5 :79-99
[3]   Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma [J].
Bansal, Ashish ;
Simpson, Eric L. ;
Paller, Amy S. ;
Siegfried, Elaine C. ;
Blauvelt, Andrew ;
de Bruin-Weller, Marjolein ;
Corren, Jonathan ;
Sher, Lawrence ;
Guttman-Yassky, Emma ;
Chen, Zhen ;
Daizadeh, Nadia ;
Kamal, Mohamed A. ;
Shumel, Brad ;
Mina-Osorio, Paola ;
Mannent, Leda ;
Patel, Naimish ;
Graham, Neil M. H. ;
Khokhar, Faisal A. ;
Ardeleanu, Marius .
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2021, 22 (01) :101-115
[4]   Dupilumab significantly improves sleep outcomes in adult patients with atopic dermatitis: results from five randomized clinical trials [J].
Beck, L. A. ;
Silverberg, J. I. ;
Simpson, E. L. ;
Yosipovitch, G. ;
Eckert, L. ;
Guillemin, I. ;
Chen, Z. ;
Ardeleanu, M. ;
Plaum, S. ;
Graham, N. ;
Ruddy, M. ;
Pirozzi, G. ;
Gadkari, A. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (02) :E130-E133
[5]   Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study [J].
Beck, Lisa A. ;
Thaci, Diamant ;
Deleuran, Mette ;
de Bruin-Weller, Marjolein ;
Chen, Zhen ;
Khokhar, Faisal A. ;
Zhang, Meng ;
Ozturk, Zafer E. ;
Shumel, Brad .
JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (03) :1608-1616
[6]   Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis [J].
Beck, Lisa A. ;
Thaci, Diamant ;
Deleuran, Mette ;
Blauvelt, Andrew ;
Bissonnette, Robert ;
de Bruin-Weller, Marjolein ;
Hide, Michihiro ;
Sher, Lawrence ;
Hussain, Iftikhar ;
Chen, Zhen ;
Khokhar, Faisal A. ;
Beazley, Bethany ;
Ruddy, Marcella ;
Patel, Naimish ;
Graham, Neil M. H. ;
Ardeleanu, Marius ;
Shumel, Brad .
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2020, 21 (04) :567-577
[7]   Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis [J].
Beck, Lisa A. ;
Thaci, Diamant ;
Hamilton, Jennifer D. ;
Graham, Neil M. ;
Bieber, Thomas ;
Rocklin, Ross ;
Ming, Jeffrey E. ;
Ren, Haobo ;
Kao, Richard ;
Simpson, Eric ;
Ardeleanu, Marius ;
Weinstein, Steven P. ;
Pirozzi, Gianluca ;
Guttman-Yassky, Emma ;
Suarez-Farinas, Mayte ;
Hager, Melissa D. ;
Stahl, Neil ;
Yancopoulos, George D. ;
Radin, Allen R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (02) :130-139
[8]   Phenotype of atopic dermatitis subjects with a history of eczema herpeticum [J].
Beck, Lisa A. ;
Boguniewicz, Mark ;
Hata, Tissa ;
Schneider, Lynda C. ;
Hanifin, Jon ;
Gallo, Rich ;
Paller, Amy S. ;
Lieff, Susi ;
Reese, Jamie ;
Zaccaro, Daniel ;
Milgrom, Henry ;
Barnes, Kathleen C. ;
Leung, Donald Y. M. .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 124 (02) :260-269
[9]   Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis [J].
Blauvelt, Andrew ;
Simpson, Eric L. ;
Tyring, Stephen K. ;
Purcell, Lisa A. ;
Shumel, Brad ;
Petro, Christopher D. ;
Akinlade, Bolanle ;
Gadkari, Abhijit ;
Eckert, Laurent ;
Graham, Neil M. H. ;
Pirozzi, Gianluca ;
Evans, Robert .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 80 (01) :158-+
[10]   Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial [J].
Blauvelt, Andrew ;
de Bruin-Weller, Marjolein ;
Gooderham, Melinda ;
Cather, Jennifer C. ;
Weisman, Jamie ;
Pariser, David ;
Simpson, Eric L. ;
Papp, Kim A. ;
Hong, H. Chih-Ho ;
Rubel, Diana ;
Foley, Peter ;
Prens, Errol ;
Griffiths, Christopher E. M. ;
Etoh, Takafumi ;
Pinto, Pedro Herranz ;
Pujol, Ramon M. ;
Szepietowski, Jacek C. ;
Ettler, Karel ;
Kemeny, Lajos ;
Zhu, Xiaoping ;
Akinlade, Bolanle ;
Hultsch, Thomas ;
Mastey, Vera ;
Gadkari, Abhijit ;
Eckert, Laurent ;
Amin, Nikhil ;
Graham, Neil M. H. ;
Pirozzi, Gianluca ;
Stahl, Neil ;
Yancopoulos, George D. ;
Shumel, Brad .
LANCET, 2017, 389 (10086) :2287-2303